The work of Mayo Clinic researcher Dr. Jan Van Deursen has shaped the understanding of age-related cell death. Dr. Jan Van Deursen has described his motivation for studying the aging process. Jan Van Deursen’s research has identified the p53 protein as the cause of age-related cell death. As cells grow older, they accumulate p53 protein, and this cellular protein becomes damaged and dies. Jan Van Deursen’s research has been published in a variety of leading journals.
Jan Van Deursen has received millions of dollars in grants from the National Institutes of Health to fund his work. In the past, Jan Van Deursen founded Unity Biotechnology, a publicly traded company focused on developing therapies for age-related diseases. The company aims to develop medicines for aging and ophthalmologic diseases. Jan Van Deursen’s lab has attracted big investors, including Jeff Bezos, the world’s richest man.
Jan Van Deursen’s research in cancer biology paved the way for developing treatments for Parkinson’s disease. Jan Van Deursen’s success in the field earned him many accolades and a respectable position among scientists. Yet, despite his high profile, Jan Van Deursen had little time for himself or his family. The cellular biologist and entrepreneur was an inspiration for many, and Jan Van Deursen inspired dozens of young researchers to pursue their careers by sharing his knowledge and skills.
After earning his Ph.D. from the University of Nijmegen, Jan Van Deursen joined the St. Jude Children’s Research Hospital in Memphis. In 1999, he established a curiosity-driven research program at Mayo Clinic. From 1999 to 2020, Jan Van Deursen served as the director of the Mayo Clinic’s transgenic and gene knockout core facility. In addition to his work in the field of aging, Dr. Jan Van Deursen mentored the work of Dr. Childs and has helped many young scientists succeed.
This groundbreaking research will change the treatment of many chronic diseases. It will lead to new treatments and a better understanding of the biology of the disease. And as a result, more people will live longer and be healthier. The research by Dr. Jan Van Deursen’s team will benefit patients and researchers worldwide. If you want to learn more about Dr. Jan Van Deursen’s work and its application to the human body, please visit his website!
Dr. Jan Van Deursen has a background in molecular biology, and his discovery of senescent cells linked aging with an accumulation of these cells in the body. Dr. Jan Van Deursen co-founded Unity Biotechnology, a publicly traded biopharmaceutical company focused on removing senescent cells. The company is gearing up to begin clinical trials for osteoarthritis. In addition, Dr. Jan Van Deursen works part-time as a researcher at Unity Biotechnology.
Dr. Jan van Deursen is a Mayo Clinic Department of Biochemistry and Molecular Biology professor. Jan Van Deursen earned his Bachelor of Science from the University of Nijmegen in the Netherlands and began independent research at St. Jude Children’s Research Hospital in 1994. There, Jan Van Deursen conducted research in the field of nuclear-cytoplasmic transport and regulated the process. Jan Van Deursen also created a mouse gene knockout core facility to study the cellular mechanisms that regulate this transport.
The breakthrough that Jan Van Deursen and his team recently achieved could help extend human life. Scientists have been looking into the role of inflammation in aging, and eliminating senescent cells from the body extends the lifespan of mice. As a result, many age-related diseases are significantly reduced. Unity Biotechnology is fortunate to have a scientist of Dr. Jan Van Deursen’s caliber on its team, and they are helping to develop new therapies for age-related illnesses.